<DOC>
	<DOCNO>NCT00312169</DOCNO>
	<brief_summary>This multicenter , open-label , non-randomized , dual-arm pilot study investigate prevalence reverse transcriptase ( RT ) resistance mutation , K65R/x L74V/x , HIV-1 plasma subject experience confirm first-time incomplete virologic suppression treatment initial antiretroviral ( ARV ) regimen consist least 12 week TDF ABC + emtricitabine ( FTC ) lamivudine ( 3TC ) + non-nucleoside reverse transcriptase inhibitor ( NNRTI ) protease inhibitor ( PI ) . Subjects followed substantial loss virologic immunologic control require treatment switch . Confirmed first-time incomplete virologic suppression define initial plasma HIV-1 RNA response &lt; 400 copies/mL , subsequent virologic rebound &gt; 400 copies/mL measure two consecutive time . Subjects screen genotype establish adherence non-suppressive TDF- ABC-containing regimen presence M184V ( treatment-related primary ) mutation demonstrate evolution treatment-emergent RT mutation characterize . Twenty subject ( maximum 10 per arm ) enrol 10-20 United States ( U.S. ) sit . If few 20 subject enrol , study may discontinue early sponsor . Equal number subject Arm A versus Arm B goal .</brief_summary>
	<brief_title>Evolution L74V K65R Mutations VIremic Subjects Tenofovir Disoproxil Fumarate ( TDF ) Abacavir ( ABC ) ( EVITA )</brief_title>
	<detailed_description>This multicenter , open-label , non-randomized , dual-arm pilot study investigate prevalence RT resistance mutation , K65R/x L74V/x , HIV-1 plasma subject experience confirm first-time incomplete virologic suppression treatment initial ARV regimen consist least 12 week TDF ABC + FTC 3TC + NNRTI PI . Subjects follow substantial loss virologic immunologic control require treatment switch . Confirmed first-time incomplete virologic suppression define initial plasma HIV-1 RNA response &lt; 400 copies/mL , subsequent virologic rebound &gt; 400 copies/mL measure two consecutive time . Subjects screen genotype establish adherence non-suppressive TDF- ABC-containing regimen presence M184V ( treatment-related primary ) mutation demonstrate evolution treatment-emergent RT mutation characterize . Twenty subject ( maximum 10 per arm ) enrol 10-20 U.S. site . If few 20 subject enrol , study may discontinue early sponsor . Equal number subject Arm A v . Arm B goal . Inclusion Criteria 1 . Confirmed first-time incomplete virologic suppression treatment least 12 week ARV regimen consist TDF ABC + FTC 3TC + NNRTI PI ( TDF Truvada individually FTC , ABC Epzicom individually 3TC ) . Confirmed first-time incomplete virologic suppression define initial plasma HIV-1 RNA response &lt; 400 copies/mL , subsequent virologic rebound &gt; 400 copies/mL measure two consecutive time . 2 . Screening HIV-1 RNA &lt; 20,000 copies/mL obtain within 30 day prior study entry . 3 . Screening CD4 cell count ≥ 200 cells/mL . 4 . Screening HIV-1 genotype M184V least one treatment-related primary mutation . 5 . Routine lab demonstrate last available lab panel : - Hemoglobin &gt; 8.0 g/dL ; - Platelet count &gt; 50,000/mm3 ; - AST ( SGOT ) &lt; 210 U/L ; - ALT ( SGPT ) &lt; 240 U/L ; - Alkaline phosphatase &lt; 625 U/L ; - Total bilirubin &lt; 3.25 mg/dL ; - Calculated creatinine clearance ≥ 50 estimate Cockcroft-Gault equation . 6 . If participate sexual activity could lead pregnancy , female study subject must use two form contraception , one must barrier method . 7 . Men woman age ≥ 18 year . 8 . Ability willingness subject give write informed consent . Exclusion Criteria 1 . Subjects screen HIV-1 genotype wild-type contains resistance mutation K65R/x L74V/x . 2 . Prior current treatment ARV regimen consist nucleoside reverse transcriptase inhibitor ( NRTIs ) , zidovudine ( ZDV ) stavudine ( d4T ) , 2 NRTIs , ritonavir-boosted dual PI regimen . 3 . Use immunomodulators ( e.g. , interleukin , interferon , cyclosporine ) , HIV vaccine , systemic cytotoxic chemotherapy , investigational therapy within 30 day prior study entry . Chronic treatment prednisone daily dose 10 mg less permitted . For non-serious illness , treatment le 21 day large dos corticosteroid permit . 4 . Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement . 5 . Serious illness require systemic treatment and/or hospitalization subject either complete therapy clinically stable therapy , opinion site investigator , least 7 day prior study entry . NOTE : Oral candidiasis , vaginal candidiasis , mucocutaneous herpes simplex , minor illness ( judge site investigator ) restriction . 6 . Unable discontinue contraindicate current medication .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Confirmed firsttime incomplete virologic suppression treatment least 12 week ARV regimen consist TDF ABC + FTC 3TC + NNRTI PI ( TDF Truvada individually FTC , ABC Epzicom individually 3TC ) . Confirmed firsttime incomplete virologic suppression define initial plasma HIV1 RNA response &lt; 400 copies/mL , subsequent virologic rebound &gt; 400 copies/mL measure two consecutive time . 2 . Screening HIV1 RNA &lt; 20,000 copies/mL obtain within 30 day prior study entry . 3 . Screening CD4 cell count ≥ 200 cells/mL . 4 . Screening HIV1 genotype M184V least one treatmentrelated primary mutation . 5 . Routine lab demonstrate last available lab panel : Hemoglobin &gt; 8.0 g/dL ; Platelet count &gt; 50,000/mm3 ; AST ( SGOT ) &lt; 210 U/L ; ALT ( SGPT ) &lt; 240 U/L ; Alkaline phosphatase &lt; 625 U/L ; Total bilirubin &lt; 3.25 mg/dL ; Calculated creatinine clearance ≥ 50 estimate CockcroftGault equation . 6 . If participate sexual activity could lead pregnancy , female study subject must use two form contraception , one must barrier method . 7 . Men woman age ≥ 18 year . 8 . Ability willingness subject give write informed consent . 1 . Subjects screen HIV1 genotype wildtype contain resistance mutation K65R/x L74V/x . 2 . Prior current treatment ARV regimen consist NRTIs , ZDV d4T , 2 NRTIs , ritonavirboosted dual PI regimen . 3 . Use immunomodulators ( e.g. , interleukin , interferon , cyclosporine ) , HIV vaccine , systemic cytotoxic chemotherapy , investigational therapy within 30 day prior study entry . Chronic treatment prednisone daily dose 10 mg less permitted . For nonserious illness , treatment le 21 day large dos corticosteroid permit . 4 . Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement . 5 . Serious illness require systemic treatment and/or hospitalization subject either complete therapy clinically stable therapy , opinion site investigator , least 7 day prior study entry . NOTE : Oral candidiasis , vaginal candidiasis , mucocutaneous herpes simplex , minor illness ( judge site investigator ) restriction . 6 . Unable discontinue contraindicate current medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>HIV</keyword>
	<keyword>NNRTI</keyword>
	<keyword>Incomplete virologic suppression</keyword>
	<keyword>treatment experience</keyword>
</DOC>